98%
921
2 minutes
20
Viral genetic diversity presents significant challenges in developing antivirals with broad-spectrum activity and high barriers to resistance. Here we report development of proteolysis targeting chimeras (PROTACs) targeting the dengue virus envelope (E) protein through coupling of known E fusion inhibitors to ligands of the CRL4 E3 ubiquitin ligase. The resulting small molecules block viral entry through inhibition of E-mediated membrane fusion and interfere with viral particle production by depleting intracellular E in infected Huh 7.5 cells. This activity is retained in the presence of point mutations previously shown to confer partial resistance to the parental inhibitors due to decreased inhibitor-binding. The E PROTACs also exhibit broadened spectrum of activity compared to the parental E inhibitors against a panel of mosquito-borne flaviviruses. These findings encourage further exploration of targeted protein degradation as a differentiated and potentially advantageous modality for development of broad-spectrum direct-acting antivirals.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11187112 | PMC |
http://dx.doi.org/10.1038/s41467-024-49161-9 | DOI Listing |
Microbiol Spectr
September 2025
Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
Modulating cell endocytosis activity to reduce host susceptibility to virus represents a promising strategy for antiviral drug development. In this study, we reveal that lactate transporter SLC16A3 is a critical host factor for reducing diverse virus invasion. By performing metabolomics, proteomics, and thermal proteome profiling experiments, AP1G1, a pivotal protein involved in cellular endocytosis, was indiscriminately screened as a chaperone of SLC16A3.
View Article and Find Full Text PDFFront Microbiol
August 2025
Guangdong Provincial Key Laboratory of Veterinary Pharmaceutics Development and Safety Evaluation, College of Veterinary Medicine, South China Agricultural University, Guangzhou, China.
Porcine reproductive and respiratory syndrome virus (PRRSV) has caused tremendous economic losses in the swine industry since emerging in the late 1980s. Although vaccination has been widely used to control PRRS epidemics in Chinese pig farms, they provided limited protection against PRRSV transmission; moreover, no effective therapeutic drugs are available. Therefore, there is an urgent need to develop novel antiviral strategies to control PRRSV epidemics.
View Article and Find Full Text PDFInfect Drug Resist
August 2025
Department of Clinical Laboratory, Affiliated Hospital of Shaoxing University, Shaoxing, 312000, People's Republic of China.
Background: commonly colonizes the genitourinary tract and primarily affects immunocompromised individuals. It is mostly confined to localized infections, with bloodstream dissemination being rare. Because of its fastidious nutritional requirements, the organism is seldom recovered by routine blood culture, and the absence of a cell wall renders it intrinsically resistant to many first-line antimicrobials.
View Article and Find Full Text PDFCureus
August 2025
Obstetrics and Gynecology, Maa N Baby Hospital, Surat, IND.
Immune reconstitution inflammatory syndrome (IRIS) is commonly described in individuals recovering from immunosuppression, particularly in HIV-positive patients initiating antiretroviral therapy. However, a similar rebound phenomenon can occur postpartum, a period marked by a shift from an immunotolerant to a pro-inflammatory state. IRIS in this context is underrecognized and may present atypically, complicating timely diagnosis.
View Article and Find Full Text PDFCureus
August 2025
Department of Gastrointestinal and Pediatric Surgery, Division of Reparative Medicine, Institute of Life Sciences, Graduate School of Medicine, Mie University, Tsu, JPN.
Conversion surgery is increasingly used for initially unresectable esophageal cancer patients responding to induction therapy. The integration of immune checkpoint inhibitors (ICIs) into standard chemotherapy regimens is expected to increase the number of patients undergoing this approach. However, ICIs can cause immune-related adverse events (irAEs), which are often difficult to diagnose in the postoperative setting.
View Article and Find Full Text PDF